PD Neurotechnology (PDN) have received EUR1.5m in funding from investor Big PiVentures SCSp. The funding will see the commercialization along with continued research and development of PDN's wearable medical technology.
The company specialises in sensors and software for the monitoring, diagnosis and treatment of movement disorders like Parkinson's disease.
MBM’s Alexander Lamley, Senior Associate, with assistance from Yavor Georgiev, Associate, from the corporate team, advised PDN on the legal aspects of receiving the funding.
President of the board of directors at PDN, Nikolaos Moschos commented: 'This additional funding will ensure the continued development of our innovative wearable medical technology that will significantly benefit Parkinson's sufferers. MBM has again provided fantastic support and legal and commercial advice. Alex Lamley and Yavor Georgiev have been instrumental in completing this deal on tight timeframes.'
Alexander Lamley added: ‘We're delighted to see PD Neurotechnology continue to advance its much needed technology allowing patients to be monitored remotely and this latest investment is testament to the company and product that Nikos and the founding team has built.’
Aristos Doxiadis, Partner at Big Pi, said: “We invest in many jurisdictions. The speed and ease of each transaction depends on the quality of legal support of the target company. MBM were first rate.The quality of their draft documents was excellent, and they responded very quickly”.
MBM Commercial advises on all aspects of corporate law with particular expertise in both acting for a range of investor companies and companies receiving investment. For further information please get in touch with Alexander Lamley, email@example.com.